RU2015138443A - Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2 - Google Patents
Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2 Download PDFInfo
- Publication number
- RU2015138443A RU2015138443A RU2015138443A RU2015138443A RU2015138443A RU 2015138443 A RU2015138443 A RU 2015138443A RU 2015138443 A RU2015138443 A RU 2015138443A RU 2015138443 A RU2015138443 A RU 2015138443A RU 2015138443 A RU2015138443 A RU 2015138443A
- Authority
- RU
- Russia
- Prior art keywords
- methylquinolin
- methyl
- oxymethyl
- composition
- phenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 19
- 208000028185 Angioedema Diseases 0.000 title claims 7
- 230000001404 mediated effect Effects 0.000 title claims 7
- 208000025047 Non-histaminic angioedema Diseases 0.000 title claims 6
- 101710085045 B2 bradykinin receptor Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 (4-chloro-3 - (((4- (4-fluoro-1H-pyrazol-1-yl) -2-methylquinolin-8-yl) oxy) methyl) -6-methylpyridin-2-yl) methyl Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 101800004538 Bradykinin Proteins 0.000 claims 7
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 7
- 102100035792 Kininogen-1 Human genes 0.000 claims 7
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010015866 Extravasation Diseases 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000036251 extravasation Effects 0.000 claims 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000010802 sludge Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 2
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 102000001399 Kallikrein Human genes 0.000 claims 2
- 108060005987 Kallikrein Proteins 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 229960001174 ecallantide Drugs 0.000 claims 2
- 108010011867 ecallantide Proteins 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- NBCISQDBUPJLTO-MDWZMJQESA-N (e)-3-(6-acetamidopyridin-3-yl)-n-[2-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide Chemical compound C1=NC(NC(=O)C)=CC=C1\C=C\C(=O)NCC(=O)NC1=CC=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C1Cl NBCISQDBUPJLTO-MDWZMJQESA-N 0.000 claims 1
- XCKWRUGRUFVXGC-NTEUORMPSA-N (e)-3-(6-acetamidopyridin-3-yl)-n-[2-[2,4-dichloro-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CNC(=O)\C=C\C1=CC=C(NC(C)=O)N=C1 XCKWRUGRUFVXGC-NTEUORMPSA-N 0.000 claims 1
- AOZUWOHAZYLXRV-CLNHMMGSSA-N (e)-n-[2-[2,4-dichloro-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]-3-phenylprop-2-enamide;hydrochloride Chemical compound Cl.C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CNC(=O)\C=C\C1=CC=CC=C1 AOZUWOHAZYLXRV-CLNHMMGSSA-N 0.000 claims 1
- LRFPQMIXTRKWGR-RVDMUPIBSA-N (e)-n-[2-[4-chloro-2-cyano-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NCC(=O)N(C)C=2C(=C(COC=3C4=NC(C)=CC=C4C=CC=3)C(Cl)=CC=2)C#N)=C1 LRFPQMIXTRKWGR-RVDMUPIBSA-N 0.000 claims 1
- HRMANULVIPULPC-OQLLNIDSSA-N (e)-n-[2-[4-chloro-2-cyano-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(C#N)C=1N(C)C(=O)CNC(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 HRMANULVIPULPC-OQLLNIDSSA-N 0.000 claims 1
- ISROIASQKHGIJZ-UHFFFAOYSA-N 2-(4-aminobutylcarbamoylamino)-n-[4-chloro-2-cyano-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound NCCCCNC(=O)NCC(=O)N(C)C1=CC=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C1C#N ISROIASQKHGIJZ-UHFFFAOYSA-N 0.000 claims 1
- QMOFUAFIOXKKNA-UHFFFAOYSA-N 2-(5-benzoyl-1-methylpyrrol-2-yl)-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)C1=CC=CC=C1 QMOFUAFIOXKKNA-UHFFFAOYSA-N 0.000 claims 1
- IKBZKTIWBYTIOT-UHFFFAOYSA-N 2-[5-(4-aminobenzoyl)-1-methylpyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)C1=CC=C(N)C=C1 IKBZKTIWBYTIOT-UHFFFAOYSA-N 0.000 claims 1
- XDSJSAQKNVFGCS-UHFFFAOYSA-N 2-[5-(4-cyanobenzoyl)-1-methylpyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)C1=CC=C(C#N)C=C1 XDSJSAQKNVFGCS-UHFFFAOYSA-N 0.000 claims 1
- NYIKMJQJOYNHLK-UHFFFAOYSA-N 2-[5-(4-cyanobenzoyl)-1-methylpyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]acetamide Chemical compound C12=NC(C)=CC=C2C=CC=C1OCC(C=1Cl)=C(Cl)C=CC=1NC(=O)CC(N1C)=CC=C1C(=O)C1=CC=C(C#N)C=C1 NYIKMJQJOYNHLK-UHFFFAOYSA-N 0.000 claims 1
- XFTJDGAYMRFSDJ-UHFFFAOYSA-N 2-[5-(4-cyanobenzoyl)-1h-pyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1)=CC=C1C(=O)C1=CC=C(C#N)C=C1 XFTJDGAYMRFSDJ-UHFFFAOYSA-N 0.000 claims 1
- DMHZOSVTCZAJGP-UHFFFAOYSA-N 2-[5-(6-cyanopyridine-3-carbonyl)-1-methylpyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)C1=CC=C(C#N)N=C1 DMHZOSVTCZAJGP-UHFFFAOYSA-N 0.000 claims 1
- VYYSWHWZVWPBKK-UHFFFAOYSA-N 2-[5-(cyclohexanecarbonyl)-1-methylpyrrol-2-yl]-n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)C1CCCCC1 VYYSWHWZVWPBKK-UHFFFAOYSA-N 0.000 claims 1
- XZERMVBWFJENLS-MHWRWJLKSA-N 4-[(e)-3-[[2-[2,4-dichloro-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]amino]-3-oxoprop-1-enyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1\C=C\C(=O)NCC(=O)N(C)C1=CC=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C1Cl XZERMVBWFJENLS-MHWRWJLKSA-N 0.000 claims 1
- YAOHXRHHUWDNDM-UHFFFAOYSA-N 4-[[2-[4-chloro-2-cyano-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]carbamoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)NCC(=O)N(C)C1=CC=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C1C#N YAOHXRHHUWDNDM-UHFFFAOYSA-N 0.000 claims 1
- 101500026352 Homo sapiens Bradykinin Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KTUYWPXXZRLSON-UHFFFAOYSA-N n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-2-[5-(2,2-dimethylpropanoyl)-1-methylpyrrol-2-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC1=CC=C(C(=O)C(C)(C)C)N1C KTUYWPXXZRLSON-UHFFFAOYSA-N 0.000 claims 1
- YJCBXDWYTZAMBB-UHFFFAOYSA-N n-[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-n-methyl-2-[1-methyl-5-(2-phenylacetyl)pyrrol-2-yl]acetamide Chemical compound C=1C=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C(Cl)C=1N(C)C(=O)CC(N1C)=CC=C1C(=O)CC1=CC=CC=C1 YJCBXDWYTZAMBB-UHFFFAOYSA-N 0.000 claims 1
- KTAARZWLIWWBTL-UHFFFAOYSA-N n-[4-chloro-2-cyano-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-2-(ethylcarbamoylamino)-n-methylacetamide Chemical compound CCNC(=O)NCC(=O)N(C)C1=CC=C(Cl)C(COC=2C3=NC(C)=CC=C3C=CC=2)=C1C#N KTAARZWLIWWBTL-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786126P | 2013-03-14 | 2013-03-14 | |
| US61/786,126 | 2013-03-14 | ||
| PCT/US2014/024540 WO2014159637A1 (en) | 2013-03-14 | 2014-03-12 | Methods of treating b2-bradykinin receptor mediated angioedema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015138443A true RU2015138443A (ru) | 2017-04-20 |
| RU2015138443A3 RU2015138443A3 (https=) | 2018-03-15 |
Family
ID=51625217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015138443A RU2015138443A (ru) | 2013-03-14 | 2014-03-12 | Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160030416A1 (https=) |
| EP (1) | EP2968308A4 (https=) |
| JP (1) | JP2016514141A (https=) |
| KR (1) | KR20150127718A (https=) |
| CN (1) | CN105228623A (https=) |
| AU (1) | AU2014244592A1 (https=) |
| BR (1) | BR112015022846A2 (https=) |
| CA (1) | CA2904052A1 (https=) |
| HK (1) | HK1220136A1 (https=) |
| MX (1) | MX2015012650A (https=) |
| RU (1) | RU2015138443A (https=) |
| WO (1) | WO2014159637A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017325986B2 (en) * | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| WO2019101906A1 (en) | 2017-11-24 | 2019-05-31 | Pharvaris B.V. | Novel bradykinin b2 receptor antagonists |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| UY38707A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina |
| US11401303B2 (en) | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| RS65427B1 (sr) | 2021-08-05 | 2024-05-31 | Pharvaris Gmbh | Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2 |
| EP4499100A1 (en) | 2022-03-25 | 2025-02-05 | Pharvaris GmbH | Therapeutic uses of bradykinin b2-receptor antagonists |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| IL315699A (en) | 2022-03-25 | 2024-11-01 | Pharvaris Gmbh | A solid composition comprising dissolved bradykinin B2 receptor antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| KR20040011549A (ko) * | 2001-06-22 | 2004-02-05 | 화이자 프로덕츠 인크. | 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물 |
| WO2003087090A2 (en) * | 2002-04-10 | 2003-10-23 | Ortho-Mcneil Pharmaceutical,Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| US20100068301A1 (en) * | 2006-11-30 | 2010-03-18 | Hutchinson John H | Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| IT1391236B1 (it) * | 2008-07-11 | 2011-12-01 | St Luso Farm D'italia Spa | Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
-
2014
- 2014-03-12 CA CA2904052A patent/CA2904052A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/024540 patent/WO2014159637A1/en not_active Ceased
- 2014-03-12 KR KR1020157029035A patent/KR20150127718A/ko not_active Withdrawn
- 2014-03-12 HK HK16108272.4A patent/HK1220136A1/zh unknown
- 2014-03-12 CN CN201480027533.7A patent/CN105228623A/zh active Pending
- 2014-03-12 MX MX2015012650A patent/MX2015012650A/es unknown
- 2014-03-12 AU AU2014244592A patent/AU2014244592A1/en not_active Abandoned
- 2014-03-12 RU RU2015138443A patent/RU2015138443A/ru not_active Application Discontinuation
- 2014-03-12 US US14/776,542 patent/US20160030416A1/en not_active Abandoned
- 2014-03-12 EP EP14776198.5A patent/EP2968308A4/en not_active Withdrawn
- 2014-03-12 JP JP2016501568A patent/JP2016514141A/ja active Pending
- 2014-03-12 BR BR112015022846A patent/BR112015022846A2/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| US20160030416A1 (en) | 2016-02-04 |
| EP2968308A1 (en) | 2016-01-20 |
| EP2968308A4 (en) | 2016-08-24 |
| BR112015022846A2 (pt) | 2017-11-07 |
| AU2014244592A1 (en) | 2015-09-24 |
| HK1220136A1 (zh) | 2017-04-28 |
| CA2904052A1 (en) | 2014-10-02 |
| KR20150127718A (ko) | 2015-11-17 |
| RU2015138443A3 (https=) | 2018-03-15 |
| CN105228623A (zh) | 2016-01-06 |
| WO2014159637A1 (en) | 2014-10-02 |
| JP2016514141A (ja) | 2016-05-19 |
| MX2015012650A (es) | 2016-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015138443A (ru) | Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2 | |
| JP2016514141A5 (https=) | ||
| TWI429436B (zh) | 使用生長激素促泌素治療或預防嘔吐之方法 | |
| US20090131481A1 (en) | Transcription Factor Modulating Compounds and Methods of Use Thereof | |
| JP7460772B2 (ja) | コロナウイルス感染症の治療方法 | |
| JP2013521286A5 (https=) | ||
| US20240059654A1 (en) | Inhibitors of the wnt/beta-catenin pathway | |
| JP2008521827A5 (https=) | ||
| RU2000131184A (ru) | Соединения, обладающие свойствами, способствующими выделению гормона роста | |
| RU2011101664A (ru) | Фармацевтическая композиция, содержащая 4-гидрокси-2-оксо-2, 3-дигидро-1, 3-бензотиазол-7-ильное соединение, для модулирования активности бета2- адренорецепторов | |
| US11779559B2 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| JP2017505293A5 (https=) | ||
| RU2008146816A (ru) | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол | |
| AR080472A1 (es) | Terapias de inhibidor de autofagia basado en tioxantona para tratar el cancer | |
| MX2024008170A (es) | Tratamiento de trastornos cardiopulmonares | |
| US20050124624A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases | |
| JP2020510660A5 (https=) | ||
| JP2005504093A5 (https=) | ||
| US12576083B2 (en) | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | |
| JP2011524362A5 (https=) | ||
| JP2016537431A5 (https=) | ||
| JP2020525413A (ja) | インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法 | |
| RU2006125746A (ru) | N-(4-карбамимидоилбензил)-2-алкокси-2-гетероциклилацетамиды в качестве ингибиторов образования факторов свертывающей системы крови xa, ixa и тромбина, индуцированного фактором viia | |
| JP2021525704A5 (https=) | ||
| CN107406409B (zh) | 泛酸酰胺类似物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180723 |